Multidrug-resistant Acinetobacter infection

Multidrug-resistant Acinetobacter baumannii infection refers to infections caused by A. baumannii strains exhibiting resistance to multiple antimicrobial agents, including carbapenems, which are typically considered last-line treatments for Gram-negative bacterial infections. The resistance is primarily mediated through mobile genetic elements and plasmid-mediated mechanisms, leading to strains classified as MDR-Ab or extensively drug-resistant (XDR-Ab) ^[1].

MDR A. baumannii primarily causes ventilator-associated pneumonia and bloodstream infections in critically ill patients. The organism employs virulence mechanisms including biofilm formation, secretion of toxins, and surface glycoconjugates that enable successful infection of host tissues. Minocycline has emerged as a treatment option for MDR-Ab infections among the limited remaining effective antibiotics ^[1][3].

MDR A. baumannii is a major concern in intensive care units where critically ill patients are particularly vulnerable. Carbapenem-resistant A. baumannii represents a worldwide problem with increasing prevalence. Outbreaks have been documented not only in hospital settings but also in livestock and community settings, indicating large strain reservoirs within and outside healthcare environments. The increase in carbapenem resistance, combined with resistance to other commonly used antibiotics, poses significant challenges for infection management and eradication ^[1].

A. baumannii is primarily a nosocomial pathogen that spreads through healthcare environments. The organism possesses molecular features that promote environmental persistence, including desiccation resistance, biofilm formation, and motility capabilities. These characteristics, along with its plastic genome that rapidly mutates under stress, enable the pathogen to thrive in healthcare settings and facilitate transmission between patients ^[2].

Prevention of MDR A. baumannii infections requires proper monitoring, infection control measures, and appropriate antibiotic stewardship. Given that carbapenem-resistant strains are often resistant to all other commonly used antibiotics, preservation of remaining effective treatment options is critical. Prevention strategies should address both hospital and community settings, as reservoirs exist outside healthcare environments ^[1].

1. 1Ibrahim S et al. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021 Oct. PMID: 34460060. doi: 10.1007/s11033-021-06690-6.PubMed: https://pubmed.ncbi.nlm.nih.gov/34460060/
2. 2Harding CM et al. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018 Feb. PMID: 29249812. doi: 10.1038/nrmicro.2017.148.PubMed: https://pubmed.ncbi.nlm.nih.gov/29249812/
3. 3Singh S et al. Minocycline and Doxycycline: More Than Antibiotics. Curr Mol Pharmacol. 2021. PMID: 33568043. doi: 10.2174/1874467214666210210122628.PubMed: https://pubmed.ncbi.nlm.nih.gov/33568043/